JP Morgan Chase’s BioNexus Gene Lab BGLC Stock Holding History
Bought
Maintained
Sold
Other funds holding BGLC
JP Morgan Chase's BGLC Position: Q3 2026 in Review
JP Morgan Chase opened a new position in BioNexus Gene Lab (BGLC) in Q3 2026: 2 shares worth $3. The stake represents ﹤0.01% of the portfolio and ranks #8145 among its holdings. This is a return to the name: JP Morgan Chase previously reported a position in BGLC as recently as Q4 2024.
JP Morgan Chase first reported a position in BGLC in Q4 2024 and has held it in 2 quarters since. The position peaked at $162 in Q4 2024. 4 funds tracked by Wall St. Rank hold BGLC as of Q3 2026.
- JP Morgan Chase held 2 shares of BioNexus Gene Lab worth $3 as of Q3 2026.
- BioNexus Gene Lab was a new JP Morgan Chase position in Q3 2026.
- BioNexus Gene Lab made up ﹤0.01% of JP Morgan Chase's portfolio in Q3 2026, its #8145 holding.
- JP Morgan Chase first reported a position in BioNexus Gene Lab in Q4 2024 and has held it in 2 quarters since.
- JP Morgan Chase's BioNexus Gene Lab position peaked at $162 in Q4 2024.
- 4 funds tracked by Wall St. Rank held BioNexus Gene Lab as of Q3 2026.
Based on JP Morgan Chase's 13F filing for Q3 2026, filed 12 Nov 2026.